April 1, 2021 – American Regent, Inc., a Daiichi Sankyo Group company, announced that Paul Diolosa assumed the role of president and CEO effective today.
In this role, Diolosa will guide the organization in its ongoing strategy for applying innovation to respond to customer needs by developing and delivering complex, hard-to-manufacture injectables and essential medicines for humans and animals.
His leadership in modernizing manufacturing operations led to promotions of increasing responsibility since he joined the company in 2008, most recently serving as SVP of Operations. Prior to joining American Regent, he served as Director of Engineering at Altana Pharmaceuticals for 10 years.
As president and CEO, he succeeds Ken Keller who transitioned to a new role as the Global Head of Oncology Business at Daiichi Sankyo, Inc. as well as his continued role as president and CEO of Daiichi Sankyo, Inc.